全文获取类型
收费全文 | 225篇 |
免费 | 24篇 |
国内免费 | 48篇 |
专业分类
儿科学 | 10篇 |
妇产科学 | 1篇 |
基础医学 | 19篇 |
口腔科学 | 3篇 |
临床医学 | 49篇 |
内科学 | 50篇 |
皮肤病学 | 2篇 |
神经病学 | 22篇 |
特种医学 | 44篇 |
外科学 | 9篇 |
综合类 | 20篇 |
预防医学 | 11篇 |
眼科学 | 2篇 |
药学 | 53篇 |
中国医学 | 1篇 |
肿瘤学 | 1篇 |
出版年
2023年 | 4篇 |
2022年 | 2篇 |
2021年 | 4篇 |
2020年 | 7篇 |
2019年 | 4篇 |
2018年 | 6篇 |
2016年 | 1篇 |
2015年 | 6篇 |
2014年 | 4篇 |
2013年 | 9篇 |
2012年 | 1篇 |
2011年 | 2篇 |
2010年 | 7篇 |
2009年 | 7篇 |
2008年 | 2篇 |
2007年 | 32篇 |
2006年 | 5篇 |
2005年 | 8篇 |
2004年 | 3篇 |
2003年 | 3篇 |
2002年 | 1篇 |
2001年 | 9篇 |
2000年 | 6篇 |
1999年 | 6篇 |
1998年 | 10篇 |
1997年 | 11篇 |
1996年 | 17篇 |
1995年 | 10篇 |
1994年 | 11篇 |
1993年 | 17篇 |
1992年 | 10篇 |
1991年 | 7篇 |
1990年 | 10篇 |
1989年 | 7篇 |
1988年 | 7篇 |
1987年 | 6篇 |
1986年 | 3篇 |
1985年 | 5篇 |
1984年 | 3篇 |
1983年 | 1篇 |
1982年 | 6篇 |
1981年 | 4篇 |
1980年 | 2篇 |
1978年 | 2篇 |
1977年 | 4篇 |
1976年 | 3篇 |
1975年 | 1篇 |
1973年 | 1篇 |
排序方式: 共有297条查询结果,搜索用时 15 毫秒
101.
102.
White CA; Halpern SE; Parker BA; Miller RA; Hupf HB; Shawler DL; Collins HA; Royston I 《Blood》1996,87(9):3640-3649
Tumor-specific anti-idiotype (anti-Id) monoclonal antibodies (MoAbs) to B-cell lymphomas have been administered to patients, resulting in significant clinical responses. However, clinical responses have been limited by the emergence of Id-negative lymphoma. To overcome the problem of tumor heterogeneity, we conducted a pilot evaluation of the safety and effectiveness of yttrium 90 (90Y)-labeled anti-Id and shared Id (sId) MoAbs in non-Hodgkin's B-cell lymphoma. Nine patients with relapsed B-cell lymphoma in whom tumor was successfully targeted with 111In-labeled anti-Id MoAb were treated with 90Y-labeled anti-Id MoAb. A total of 19 courses (one to four per patient) were administered using 1,000 to 2,320 mg unlabeled clearing MoAb and 10 to 54 mCi 90Y MoAb per patient. Two of nine patients had a complete response, one a partial response, three stable disease, and three disease progression. Time to progression varied from 1 to 12 months. Toxicities were predominately hematologic, and only one patient developed infection and required transfusion. At progression, three of five assessable patients had Id- positive lymphoma and two had Id-negative lymphoma. Human antimouse antibodies (HAMA) did not develop in the patients after treatment. 90Y anti-Id MoAbs demonstrated excellent in vivo stability, produced significantly tumor regression in three of nine patients, exhibited acceptable toxicities, and elicited no HAMA formation. Further investigation of repetitive, low-dose 90Y anti-Id and MoAb therapy is warranted; however, the advantages of a pan B MoAb may prove the latter to be the agent of choice for the radio immunotherapy of B-cell lymphoma. 相似文献
103.
XG Guan XQ Guan K Feng R Jian D Tian D Tian HB Tong X Sun 《African health sciences》2013,13(3):560-564
Background
Angiocidin plays a key role in angiogenesis and tumor progression. High angiocidin expression is detected in some kind of solid tumors and tumor vascular endothelial cells. Several reports have shown the inhibition of angiogenesis and tumor growth caused by angiocidin. However, the role of angiocidin in liver cancers growth is still unclear.Objectives
To examine angiocidin expression in SMMC-7221 and HepG2 cells and the role of angiocidin in liver cancer cell growth.Methods
RT-PCR and western blot are used in this study to detect angiocidin expression. SiRNA and MTT experiments are used in exploring the role of angiocidin in tumor cell growth.Results
Our study showed high angiocidin expression in two kinds of liver cancer cells. Angiocidin protein production in HepG2 cells were reduced significantly by siRNA. When HepG2 cells were transfected with siRNA-angiocidin, these cells showed very low proliferation activity compared with control cells. Our study suggests that reduction of angiocidin may contribute to decreased proliferation activity in liver cancer cells.Conclusion
Angiocidin is highly expressed in liver cancer cells, and it may play a key role in tumor growth of liver cancers. 相似文献104.
PC Kayange HB Nkume A Feyi-Waboso K Kalua G Msukwa M Schwering Schulze 《Malawi medical journal : the journal of Medical Association of Malawi》2014,26(3):60-62
Objective
Primary open angle glaucoma (POAG) is the most common type of glaucoma in Africa. We carried out a study to determine the clinical presentation pattern of patients with primary open angle glaucoma (POAG) at a tertiary hospital in Malawi.Design
A cross-sectional studySetting
Lions Sight First Eye Hospital—a major referral and teaching state eye hospital in Blantyre, MalawiSubjects
Study participants were newly diagnosed POAG patients at specialist eye clinic during study period.Results
A total of 60 POAG patients were recruited into the study. The mean age was 58.7 years (SD= 16.6, range 18 - 86). There were more male (44, 73.3%) than female (16, 27.7%) patients. The majority of patients (73%) presented one year after onset of visual symptoms. Twenty-six patients (43%) had unilateral blindness (visual acuity < 3/60; WHO classification), while nine patients (15%) presented with bilateral blindness. A vertical cup-to-disc ratio (CDR) of 0.8 or worse was seen in 92 eyes (79%). The mean intraocular pressure (IOP) reading was 35.5 mmHg (SD 13.30). Of the thirty-three eyes that successfully underwent visual field analysis, very advanced defects were recorded in 12 eyes (36%).Conclusion
This study demonstrates delayed presentation and male predominance among POAG patients at a tertiary eye hospital in Malawi. Glaucoma intervention programmes should aim at identifying patients with treatable glaucoma with particular attention to women. 相似文献105.
Joshua D. Niznik PharmD PhD Jacob N. Hunnicutt PhD Xinhua Zhao PhD Maria K. Mor PhD Florentina Sileanu MS Sherrie L. Aspinall PharmD MSc Sydney P. Springer PharmD MS Mary J. Ersek PhD RN Walid F. Gellad MD MPH Loren J. Schleiden MS Joseph T. Hanlon PharmD MS Joshua M. Thorpe PhD MPH Carolyn T. Thorpe PhD MPH 《Journal of the American Geriatrics Society》2020,68(4):736-745
106.
Carolyn T. Thorpe PhD MPH Florentina E. Sileanu MS Maria K. Mor PhD Xinhua Zhao PhD Sherrie Aspinall PharmD MSc Mary Ersek PhD RN Sydney Springer PharmD MS Joshua D. Niznik PharmD PhD Michelle Vu PharmD MPH Loren J. Schleiden MS Walid F. Gellad MD MPH Jacob Hunnicutt PhD Joshua M. Thorpe PhD MPH Joseph T. Hanlon PharmD MS 《Journal of the American Geriatrics Society》2020,68(11):2609-2619
107.
Diabetes mellitus encompasses a group of chronic metabolic conditions associated with cardiovascular complications such as atherosclerosis, cardiomyopathy and nephropathy. In the present study, the authors investigated the beneficial effects of swertiamarin in diabetes and its associated cardiovascular complications in Zucker fa/fa rats. Six male Zucker fa/fa rats in each group were treated for 28 days with swertiamarin (75 mg/kg/day, intraperitoneally) or pioglitazone (30 mg/kg orally). Blood samples were collected and evaluated for several parameters. Elevated serum glucose, triglyceride, nonesterified free-fatty acid and cholesterol levels were found in untreated Zucker fa/fa rats. Serum matrix metalloproteinase (MMP)-9 and MMP-3 levels were also found to be significantly higher in untreated Zucker fa/fa rats. Treatment with swertiamarin significantly (P<0.05) reduced serum glucose, triglyceride, nonesterified free-fatty acid and cholesterol levels, and also reduced serum MMP-9 and MMP-3 levels compared with untreated rats. Swertiamarin also significantly (P<0.05) decreased serum levels of urea compared with untreated Zucker fa/fa rats. Overall, the data suggest that swertiamarin produced beneficial effects with respect to diabetes-induced cardiovascular complications such as atherosclerosis and nephropathy. A swertiamarin-induced decrease in serum MMP-9 and MMP-3 levels is one of the possible mechanisms responsible for improvement of these complications. 相似文献
108.
用放射配体受体结合法测定表明:克塞平对多巴胺D1受体的亲和力较异戊塞平高近20倍。两药对其它各受体的亲和力差別不大。慢性给药后,异戊塞平和克塞平均能使大鼠脑皮层5-HT2受体的密度显著下降,而亲和力变化不明显。这种下调5-HT2受体的作用发生在给异戊塞平后1~2周之间,给克塞平后的2~3周之间。慢性给药3周,异戊塞平和克塞平均未使大鼠脑皮层的β受体密度及亲和力产生显著变化。 相似文献
109.
J L Neumeyer N Baindur J Yuan G Booth P Seeman H B Niznik 《Journal of medicinal chemistry》1990,33(2):521-526
In an earlier paper, we reported the development of (+-)-7-iodo-8-hydroxy-3-methyl-1-(4'-azidophenyl)-2,3,4,5-tetrahydro- 1H-3-benzazepine (I-MAB) and its 125I analogue ([125I]I-MAB) as selective, high affinity photoaffinity labels for the D-1 dopamine receptor. In this report, we now describe the complete synthesis and resolution of I-MAB and the pharmacological characterization of the stereoisomers in canine striatal membranes. R-(+)-I-MAB showed highly specific dopamine D-1 receptor binding (KD = 0.28 nM) and binds selectively and stereoselectively to the D-1 receptor. These results further confirm the previous suggestion that, in the benzazepine series of DA agonists and antagonists, the activity principally resides in the R-(+) enantiomer, the S-(-) enantiomer being considerably less potent or inactive. Moreover, R-(+)-[125I]I-MAB, upon photolysis, identifies the ligand-binding subunits of the neuronal D-1 receptor, with an apparent Mr of 74,000, 62,000, and 51,000 as assessed by autoradiography following sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Photoincorporation of R-(+)-[125I]I-MAB into these polypeptides was stereoselectively blocked by D-1 dopaminergic ligands with an appropriate pharmacologic profile for the receptor. R-(+)-[125I]I-MAB should thus prove to be a useful stereoselective photoaffinity label for the further characterization of the D-1 receptors. 相似文献
110.